Celldex Therapeutics (CLDX) Interest & Investment Income (2012 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Interest & Investment Income of -$1.1 million for Q1 2026, down 534.65% year-over-year from $254000.0 in Q1 2025, and up 95.09% quarter-over-quarter from -$22.5 million in Q4 2025.
Celldex Therapeutics (CLDX) Interest & Investment Income (2012 - 2026) Analysis & Trends
Celldex Therapeutics' Interest & Investment Income history runs 15 years deep, the most recent figure standing at -$1.1 million for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 534.65% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at -$17.2 million (down 144.69% YoY), while the FY2025 annual figure was $312000.0, down 99.16% from the prior year.
- Interest & Investment Income for Q1 2026 stood at -$1.1 million, up from -$22.5 million in the prior quarter.
- The five-year high for Interest & Investment Income was $35.2 million in Q4 2024, with the low at -$22.5 million in Q4 2025.
- The 5-year median for Interest & Investment Income is $63000.0 (2023), against an average of $1.5 million.
- The sharpest annual moves came in 2022 and 2024: Interest & Investment Income plunged 89000.0% in 2022, then soared 5468.25% in 2024.
- Celldex Therapeutics' Interest & Investment Income stood at $1.4 million in 2022, then surged by 214.94% to $4.3 million in 2023, then jumped by 715.44% to $35.2 million in 2024, then sank by 163.75% to -$22.5 million in 2025, then soared by 95.09% to -$1.1 million in 2026.
- Business Quant data shows CLDX's Interest & Investment Income at -$1.1 million in Q1 2026, -$22.5 million in Q4 2025, and $6.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | 7.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.12 Mn |
| Mar 31, 2026 | -1.10 Mn |
| Dec 31, 2025 | -22.46 Mn |
| Sep 30, 2025 | 6.57 Mn |
| Jun 30, 2025 | -229,000.00 |
| Mar 31, 2025 | 254,000.00 |
| Dec 31, 2024 | 35.24 Mn |
| Sep 30, 2024 | 3.51 Mn |
| Jun 30, 2024 | -464,000.00 |
| Mar 31, 2024 | -1.06 Mn |
| Dec 31, 2023 | 4.32 Mn |
| Sep 30, 2023 | 63,000.00 |
| Jun 30, 2023 | -51,000.00 |
| Mar 31, 2023 | 863,000.00 |
| Dec 31, 2022 | 1.37 Mn |
| Sep 30, 2022 | 305,000.00 |
| Jun 30, 2022 | -529,000.00 |
| Mar 31, 2022 | -1.78 Mn |
| Dec 31, 2021 | -654,000.00 |
| Sep 30, 2021 | 145,000.00 |